Fulvestrant
- Generic Name
- Fulvestrant
- Brand Names
- Faslodex, Fulvestrant Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C32H47F5O3S
- CAS Number
- 129453-61-8
- Unique Ingredient Identifier
- 22X328QOC4
- Background
Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatme...
- Indication
For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
- Associated Therapies
- -
Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2021-04-23
- Lead Sponsor
- Haihe Biopharma Co., Ltd.
- Target Recruit Count
- 228
- Registration Number
- NCT04856371
Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.
- First Posted Date
- 2021-04-21
- Last Posted Date
- 2021-04-21
- Lead Sponsor
- Blokhin's Russian Cancer Research Center
- Target Recruit Count
- 1000
- Registration Number
- NCT04852081
- Locations
- 🇷🇺
N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russian Federation
Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Marina N Sharifi
- Target Recruit Count
- 44
- Registration Number
- NCT04762979
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸University of Illinois Cancer Center, Chicago, Illinois, United States
🇺🇸University of Wisconsin, Madison, Wisconsin, United States
Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)
- Conditions
- Interventions
- First Posted Date
- 2021-02-04
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 11
- Registration Number
- NCT04738292
- Locations
- 🇺🇸
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
🇺🇸Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 52
- Registration Number
- NCT04726332
- Locations
- 🇺🇸
Exelixis Clinical Site #2, Dallas, Texas, United States
🇺🇸Exelixis Clinical Site #4, Atlanta, Georgia, United States
🇺🇸Exelixis Clinical Site #3, Boston, Massachusetts, United States
A Study of Abemaciclib in Indian Women With Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-01-13
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 200
- Registration Number
- NCT04707196
- Locations
- 🇮🇳
Nirmal Hospital Pvt Ltd., Surat, Gujarat, India
🇮🇳Meditrina Institute of Medical Sciences, Nagpur, Maharashtra, India
🇮🇳Rajiv Gandhi Cancer Institute And Research Centre, New Delhi, Delhi, India
Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor
- Conditions
- Interventions
- First Posted Date
- 2020-12-02
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 250
- Registration Number
- NCT04650581
- Locations
- 🇨🇦
QEII Health Sciences Centre, Halifax, Nova Scotia, Canada
🇨🇦Centre Integre de Sante et de Services Sociaux, Greenfield Park, Quebec, Canada
🇨🇦CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-10-28
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 186
- Registration Number
- NCT04606446
- Locations
- 🇺🇸
Thomas Jefferson University, Gibbon Building, Philadelphia, Pennsylvania, United States
🇺🇸Thomas Jefferson University, Investigational Drug Service, Philadelphia, Pennsylvania, United States
🇺🇸Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Research Organization, Philadelphia, Pennsylvania, United States
ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL
- Conditions
- Interventions
- First Posted Date
- 2020-10-26
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- MedSIR
- Target Recruit Count
- 162
- Registration Number
- NCT04603183
- Locations
- 🇪🇸
Hospital Clinico Universitario de Valencia, Valencia, Spain
🇮🇹Instituto Europeo di Oncologia, Milano, Italy
🇮🇹Azienda Ospedaliero-Universitaria Cittá de la Salute e della Scienza, Torino, Italy
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
- Conditions
- Interventions
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 217
- Registration Number
- NCT04579380
- Locations
- 🇺🇸
HealthPartners Institute, Saint Louis Park, Minnesota, United States
🇺🇸Texas Oncology, P.A. - Dallas, Dallas, Texas, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.